All In Biotech

Drug Trial Radar · NCT03645928

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

225

Actual

Start

May 7, 2019

Primary completion

Feb 20, 2026

Study completion Feb 20, 2026

Sponsor

Lead sponsor
Iovance Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.

Conditions

  • Metastatic Melanoma
  • Squamous Cell Carcinoma of the Head and Neck
  • Non-small Cell Lung Cancer

Interventions

  • LifileucelBiological

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor-infiltrating lymphocytes (TIL). After NMA-LD, patients receive lifileucel, followed by aldesleukin administration. Lifileucel will be administered to patients once (on Day 0) during the study.

  • LN-145Biological

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.

  • PembrolizumabDrug

    Humanized antibody. Pembrolizumab will be administered after tumor resection and will continue every 3 weeks or every 6 weeks for up to 2 years.

  • LN-145-S1Biological

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of TIL, then TIL with high levels of PD-1 surface expression are selected. After NMA-LD, patients receive their autologous PD-1-selected TIL (LN-145-S1), followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.

  • IpilimumabDrug

    Monoclonal antibody Ipilimumab will be administered as a single dose prior to tumor resection.

  • NivolumabDrug

    Monoclonal antibody. Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to starting NMA-LD and will continue every 4 weeks for up to 2 years.

  • Nivolumab-relatlimabDrug

    Monoclonal antibody (nivolumab) and monoclonal antibody (relatlimab). Nivolumab-relatlimab will be administered after tumor resection and will continue every 4 weeks for up to 2 years.

  • CisplatinDrug

    Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • CarboplatinDrug

    Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • PaclitaxelDrug

    Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • Nab paclitaxelDrug

    Nab-Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • PemetrexedDrug

    Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if applicable.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: Up to 60 months
  2. Safety Profile Measured by Grade ≥3 TEAEsTime frame: Up to 60 months
  3. Percentage of patients for whom lifileucel is successfully manufactured and meets release specificationTime frame: Up to 60 months

Locations

34 sites in 7 countries. Site status is shown where the registry gives one.

  • University of California, San Diego

    La Jolla, California

  • University of Southern California

    Los Angeles, California

  • University of California, Los Angeles

    Los Angeles, California

  • University of Colorado

    Denver, Colorado

  • Yale University

    New Haven, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Louisville

    Louisville, Kentucky

  • University of Maryland

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • MD Anderson at Cooper

    Camden, New Jersey

  • Morristown Medical Center

    Morristown, New Jersey

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Ohio State University

    Columbus, Ohio

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Universitätsklinikum Schleswig-Holstein - Campus Lübeck

    Lübeck, Schleswig-Holstein, Germany

  • Laiko General Hospital of Athens

    Athens, Attica, Greece

  • Attikon University General Hospital

    Athens, Attica, Greece

  • ICO l'Hospitalet - Hospital Duran i Reynals

    Barcelona, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, Spain

  • Hospital Regional Universitario de Malaga - Hospital General

    Málaga, Málaga, Spain

  • Universitaetsspital Bern

    Bern, Switzerland

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Switzerland

  • Guy's Hospital

    London, England, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    London, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.